There are 110 clinical-stage psychedelic drug stocks trading on North American stock exchanges (see here) of which 64 research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (see here), 40 research the treatment of illnesses based on the use of THC marijuana and 6 are focused on the development and operation of treatment clinics. 

The 8 stocks in the munKNEE Psychedelic Compounds-Based Drug Stocks Index are those that have market caps in excess of $50M. They went UP 18.5% in August (July 29th to September 2nd) and are now UP 41.6% since the end of June, albeit DOWN 35.7% YTD.

Below is how the constituents performed in August, in descending order, and since the end of June:

1. Cybin (CYBN): UP 79.7% in August; UP 89.3% since the end of June
   • Is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
2. GH Research (GHRS): UP 42.4% in August; UP 59.2% since the end of June
   • Is focused on developing novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
3. Seelos (SEEL): UP 35.7% in August; UP 67.6% since the end of June
   • Is focused on developing products that address significant unmet needs in the Central Nervous System disorders and other rare disorders.
4. Atai (ATAI): UP 13.0% in August; UP 19.8% since the end of June
   • Is focused on acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
5. Mind Medicine (MNMD): UP 10.9% in August; UP 19.6% since the end of June
   • Is focused on discovering, developing, and deploying the next generation of psychedelic-inspired medicines and therapies to address addiction and mental illness development.
   • Underwent a 1-for-15 reverse stock exchange on August 29th.
6. Compass Pathways (CMPS): UP 7.6% in August; UP 55.0% since the end of June
   • Is focused on the development of a new model of psilocybin therapy for people with treatment-resistant depression, in which psilocybin is administered in conjunction with psychological support.
7. Zynerba (ZYNE): UP 1.8% in August; UP 1.8% since the end of June
   • Is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery.
8. Allied Corp. (ALID): DOWN 21.8% in August; DOWN 10.4% since the end of June
   • Is focused on the research, development, and production of cannabinoid health solutions in the United States and has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder.

In total, the munKNEE Psychedelic Compounds-Based Drug Stock Index went UP 18.5% in August and is UP 41.6% since the end of June, but is still DOWN 35.7% YTD.

As mentioned in the opening paragraph, 6 psychedelic companies are primarily focused on the development, expansion and operation of therapy clinics to capitalize on the massive commercial opportunity that exists to treat the plus two billion people worldwide who suffer from chronic pain, addiction and substance abuse withdrawal, and depression (see here). 5 of those companies use the psychedelic compound ketamine (see here) while the other plans to treat its patients with ibogaine, a naturally-occurring molecule derived from the root bark of the iboga tree. 

More By This Author:

Uptrend In Major Canadian Cannabis LPs Continues
How The 5 Cannabis Categories Performed Last Week
Plant-Based Food Stocks Continue To Crater: -13.4% This Week